XML 19 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1

Note 5 - Realignment of Goals and Objectives and New Development Focus	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	5. Realignment of Goals and Objectives and New Development Focus Following the approval of SUSTOL and consistent with our transition into a commercial -stage biotechnology company, we realigned our goals and objectives and refocused our development efforts to the area of postoperative pain management. On October 18, 2016, we entered into a lease agreement for new office and laboratory space in San Diego, California, which became our corporate headquarters in December 2016. On September 30, 2016, the board of directors accepted the resignations of three executive officers, and these executive officers and other employees directly affected by the realignment and refocusing were or will be provided with one -time severance payments upon termination, continued benefits for a specified period of time and outplacement assistance. We expect to incur total expenses of $9.9 million in connection with these activities, $6.0 million of which is primarily for severance, and $3.9 million of which is for non-cash, stock-based compensation expense. From September 30, 2016 through September 30, 2017 we have recognized a total expense of $9.7 million. The remaining $0.2 million relates to employees who are being retained until the fourth quarter of 2017 and is being expensed on a straight-line basis over the retention period. We expect to make the final payment resulting from the realignment of our goals and objectives and new development focus in the second quarter of 2018. As of September 30, 2017, we have paid $4.5 million of the total $6.0 million cash charges. For the three months ended September 30, 2017, total expenses related to the realignment were $0.2 million, which were included in research and development expense. For the nine months ended September 30, 2017, total expenses related to the realignment were $1.9 million, with $1.6 million included in research and development expense and $0.3 million in general and administrative expense. The expenses we expect to incur are subject to a number of assumptions, and actual results may materially differ. We may also incur other material expenses not currently contemplated due to events that may be associated with, or result from, the realignment of our goals and objectives and new development focus. We have accounted for these expenses in accordance with Accounting Standard Codification No. 420, Exit or Disposal Cost Obligations .

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-URI http://asc.fasb.org/topic&trid=2175745

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration